GROSS LAW FIRM

FibroGen, Inc. Loss Submission Form

The Gross Law Firm notifies investors that a class action has commenced in the United States District Court for the Middle District of North Carolina on behalf of shareholders of FibroGen, Inc. who purchased shares between October 18, 2017 and April 6, 2021.

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company’s prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia certain safety analyses submitted in connection with CKD included post-hoc changes to the stratification factors; (ii) FibroGen’s analyses with the pre-specified stratification factors result in higher hazard ratios (point estimates of relative risk) and 95% confidence intervals; (iii) based on these analyses the Company could not conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa; (iv) as a result, the Company faced significant uncertainty that its NDA for roxadustat as a treatment for anemia of CKD would be approved by the FDA; and (v) as a result of the foregoing, Defendants’ statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action. Appointment as Lead Plaintiff is not required to partake in any recovery.

Shareholders have until June 11, 2021 to request that the court appoint them lead plaintiff.

To receive more information, please fill out the form.

The Gross Law Firm does not share your information with others. There is no other or obligation for you to submit.

Name

Email

Physical Address

Phone Number

Shares Owned

Purchase Date

Loss

This submission does not create an attorney-client relationship. If we believe that you might be an appropriate lead plaintiff, we will contact you to discuss whether to establish an attorney-client relationship.